Outlook Therapeutics Inc. (OTLK) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Outlook Therapeutics Inc. (NASDAQ: OTLK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.47 (-5.15% 1D, market cap $120.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OTLK ranks #585 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OTLK carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 4.0%, and ROIC of -35.0%. By comparison, AVXL (Anavex Life Sciences Corp.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $120.5M) and ARMP (Armata Pharmaceuticals Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $120.8M). Among the 5-stock peer group, OTLK leads on earnings multiple (N/A) while LENZ leads on capital efficiency (-27.8% ROIC).
Per OTLK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001649989), Outlook Therapeutics Inc. generated $1.4M in revenue, -$62.4M in net income, and -$51.8M in free cash flow against $18.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 4% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While OTLK currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.60) and Max Pain ($0.49) forces dealer call-delta covering toward $2.67.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Outlook Therapeutics Inc. (OTLK) dropped -5.15% to $0.47, trading at 13% of its 52-week range ($0.16 – $2.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg)ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, In
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE)
Kevin Lundquist Kevin Lundquist Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep exp
Yahoo Finance coverage on OTLK stock catalysts, institutional flow, and earnings outlook.
The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including broad
Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-v
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™ Access the segment here ISELIN, N.J., Oct. 06, 2026 (GLOBE NEWS
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeuti
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OTLK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OTLK. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Outlook Therapeutics Inc. (OTLK) ranks #585 by composite RQD confidence (38/100, grade D-) and #636 by equity capitalization ($120.1M). Within this direct 5-issuer industry benchmark cohort, OTLK leads on earnings valuation at N/A trailing P/E, while LENZ leads on capital efficiency and profitability with -27.8% ROIC and 96.0% gross margin. LENZ currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with OTLK at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OTLK
ACTIVE
Outlook Therapeutics Inc. | D- | 38/100 | — | 4.0% | -35.0% | -5.15% | $120.1M | Benchmark Subject |
| AVXL Anavex Life Sciences Corp. | E | 32/100 | — | — | -35.0% | -8.46% | $120.5M | /avxl-vs-otlk → |
| ARMP Armata Pharmaceuticals Inc. | D- | 43/100 | — | — | -35.0% | +0.92% | $120.8M | /armp-vs-otlk → |
| HUMA Humacyte Inc. | E | 31/100 | — | -30.0% | -35.0% | -12.47% | $130.5M | /huma-vs-otlk → |
| LENZ LENZ Therapeutics Inc. | D | 44/100 | — | 96.0% | -27.8% | -12.61% | $109.7M | /lenz-vs-otlk → |
In its most recent audited fiscal period (FY2025, filed 2025-09-30), Outlook Therapeutics Inc. (OTLK) reported GAAP revenue of $1.4M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$62.4M, operating cash flow of -$51.8M, and free cash flow of -$51.8M (+24.7% YoY). On the balance sheet, OTLK closed FY2025 with $18.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $1.4M | -$62.4M | -$51.8M | -$51.8M | $18.2M | — |
| FY2024 (FY) | 2024-09-30 | $0 | -$75.4M | -$68.8M | -$68.8M | $17.0M | — |
| FY2023 (FY) | 2023-09-30 | $0 | -$59.0M | -$43.0M | -$43.0M | — | — |
As of 2026-11-02, Outlook Therapeutics Inc. (NASDAQ: OTLK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.47 (-5.15% 1D, market cap $120.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OTLK ranks #585 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OTLK carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 4.0%, and ROIC of -35.0%. By comparison, AVXL (Anavex Life Sciences Corp.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $120.5M) and ARMP (Armata Pharmaceuticals Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $120.8M). Among the 5-stock peer group, OTLK leads on earnings multiple (N/A) while LENZ leads on capital efficiency (-27.8% ROIC).
Per OTLK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001649989), Outlook Therapeutics Inc. generated $1.4M in revenue, -$62.4M in net income, and -$51.8M in free cash flow against $18.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
OTLK last traded at $0.47 (-5.15% on volume of 4,794,550 shares), positioning the stock -21.67% below its 50-day simple moving average ($0.60) and -28.79% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.16 to $2.54, OTLK sits at the 13.0% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.53).
Why OTLK Stock dropped -5.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD 5-pillar rating engine, Outlook Therapeutics Inc. (OTLK) carries a composite score of 38/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $0.47 (-5.15%). Fundamental cash generation scores 8/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 11/20, insider conviction scores 3/20, macro regime alignment scores 8/20 (Beta 1.00), and forensic balance-sheet protection scores 8/20 (Altman Z-Score N/A, Piotroski F-Score 2/9).
Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Biological Products (No Diagnostic Substances), upside depends on sustained operating margin expansion (-60.0%) and free cash flow conversion relative to the 52-week range of $0.16 – $2.54.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), OTLK is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin 4.0%), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).
Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.
Real-time company headlines, analyst actions, and sector developments for Outlook Therapeutics Inc. (OTLK) • Click "Debate This Headline" to argue it in the Roar Pit below
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg)ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, In
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE)
Kevin Lundquist Kevin Lundquist Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep exp
Yahoo Finance coverage on OTLK stock catalysts, institutional flow, and earnings outlook.
The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including broad
Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-v
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Welcome to the OTLK (Outlook Therapeutics Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on OTLK, but look at what you are paying: current EV/EBITDA multiples with 4.0% gross margins. Unless Outlook Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on OTLK, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.47 (52-wk range $0.16 - $2.54), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).